Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could ease daily struggles of myasthenia gravis

NCT ID NCT06517758

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 13, 2026 · Updated 3 times

Summary

This study tests an oral drug called iptacopan in people with generalized myasthenia gravis (gMG) who are already on standard treatment. About 146 adults will receive either iptacopan or a placebo for 6 months to see if it improves their ability to do daily activities and reduces muscle weakness. The goal is to find a new way to better control this chronic autoimmune disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
iptacopan
What this could lead to
If it works, iptacopan could offer a new oral treatment option to better control symptoms of generalized myasthenia gravis.
What could go wrong
This is a Phase 3 trial, but it's still experimental. It may not prove more effective than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENERALIZED MYASTHENIA GRAVIS

Contacts and locations

Locations

  • Augusta University Georgia

    Augusta, Georgia, 30912, United States

  • California Pacific Medical Center

    Sacramento, California, 94115, United States

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • Fullerton Neuro and Headache Ctr

    Fullerton, California, 92835, United States

  • Henry Ford Health System

    Detroit, Michigan, 48202, United States

  • Honor Health Research Institute

    Scottsdale, Arizona, 85258, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Mid Atlantic Epilepsy and Sleep Ctr

    Bethesda, Maryland, 20817-1807, United States

  • Nerve and Muscle Center of Texas

    Houston, Texas, 77030, United States

  • Novartis Investigative Site

    CABA, Buenos Aires, C1428AQK, Argentina

  • Novartis Investigative Site

    Córdoba, Córdoba Province, X5004AOA, Argentina

  • Novartis Investigative Site

    Rosario, Santa Fe Province, 2000, Argentina

  • Novartis Investigative Site

    Buenos Aires, C1012AAR, Argentina

  • Novartis Investigative Site

    Caba, C1055AAF, Argentina

  • Novartis Investigative Site

    Caba, C1182, Argentina

  • Novartis Investigative Site

    Capital Federal, C1023AAB, Argentina

  • Novartis Investigative Site

    Córdoba, X5004CDT, Argentina

  • Novartis Investigative Site

    Camperdown, Sydney, NSW 2050, Australia

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, 90035-903, Brazil

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, 90560-030, Brazil

  • Novartis Investigative Site

    Joinville, Santa Catarina, 89202-165, Brazil

  • Novartis Investigative Site

    Bahia, 40290-000, Brazil

  • Novartis Investigative Site

    São Paulo, 04038-002, Brazil

  • Novartis Investigative Site

    Hefei, Anhui, 230001, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, 510515, China

  • Novartis Investigative Site

    Shenzhen, Guangdong, 518053, China

  • Novartis Investigative Site

    Shijiazhuang, Hebei, 50030, China

  • Novartis Investigative Site

    Changsha, Hunan, 410008, China

  • Novartis Investigative Site

    Suzhou, Jiangsu, 215004, China

  • Novartis Investigative Site

    Xi'an, Shaanxi, 710075, China

  • Novartis Investigative Site

    Xianyang, Shaanxi, 712000, China

  • Novartis Investigative Site

    Beijing, 100034, China

  • Novartis Investigative Site

    Beijing, 100070, China

  • Novartis Investigative Site

    Beijing, 100730, China

  • Novartis Investigative Site

    Fujian, 350001, China

  • Novartis Investigative Site

    Jinan, 250012, China

  • Novartis Investigative Site

    Copenhagen, DK-2100, Denmark

  • Novartis Investigative Site

    Limoges, Haute Vienne, 87000, France

  • Novartis Investigative Site

    Garches, 92380, France

  • Novartis Investigative Site

    Nice, 06000, France

  • Novartis Investigative Site

    Paris, 75013, France

  • Novartis Investigative Site

    Paris, 75940, France

  • Novartis Investigative Site

    Munich, Bavaria, 81675, Germany

  • Novartis Investigative Site

    Regensburg, Bavaria, 93053, Germany

  • Novartis Investigative Site

    Würzburg, Bavaria, 97070, Germany

  • Novartis Investigative Site

    Frankfurt am Main, Hesse, 60590, Germany

  • Novartis Investigative Site

    Bochum, 44789, Germany

  • Novartis Investigative Site

    Bochum, 44791, Germany

  • Novartis Investigative Site

    Essen, 45147, Germany

  • Novartis Investigative Site

    Athens, 115 28, Greece

  • Novartis Investigative Site

    Chaïdári, 124 62, Greece

  • Novartis Investigative Site

    Larissa, 411 10, Greece

  • Novartis Investigative Site

    Thessaloniki, 54636, Greece

  • Novartis Investigative Site

    Haifa, 3109601, Israel

  • Novartis Investigative Site

    Jerusalem, 9112001, Israel

  • Novartis Investigative Site

    Bologna, BO, 40139, Italy

  • Novartis Investigative Site

    Florence, FI, 50134, Italy

  • Novartis Investigative Site

    Genova, GE, 16132, Italy

  • Novartis Investigative Site

    Milan, MI, 20133, Italy

  • Novartis Investigative Site

    Palermo, PA, 90127, Italy

  • Novartis Investigative Site

    Palermo, PA, 90146, Italy

  • Novartis Investigative Site

    Roma, RM, 00133, Italy

  • Novartis Investigative Site

    Roma, RM, 00135, Italy

  • Novartis Investigative Site

    Roma, RM, 00189, Italy

  • Novartis Investigative Site

    Orbassano, TO, 10043, Italy

  • Novartis Investigative Site

    Chiba, Chiba, 2608677, Japan

  • Novartis Investigative Site

    Narita, Chiba, 286-8520, Japan

  • Novartis Investigative Site

    Sapporo, Hokkaido, 0630005, Japan

  • Novartis Investigative Site

    Nishinomiya, Hyōgo, 6638501, Japan

  • Novartis Investigative Site

    Hanamaki, Iwate, 0250082, Japan

  • Novartis Investigative Site

    Sendai, Miyagi, 9838520, Japan

  • Novartis Investigative Site

    Suita, Osaka, 5650871, Japan

  • Novartis Investigative Site

    Higashi-Matsuyama, Saitama, 355-0005, Japan

  • Novartis Investigative Site

    Shinjuku Ku, Tokyo, 160-0023, Japan

  • Novartis Investigative Site

    Fukuoka, 8128582, Japan

  • Novartis Investigative Site

    Fukushima, 9601295, Japan

  • Novartis Investigative Site

    Hiroshima, 7348551, Japan

  • Novartis Investigative Site

    Lublin, Lublin Voivodeship, 20-064, Poland

  • Novartis Investigative Site

    Warsaw, Masovian Voivodeship, 02-676, Poland

  • Novartis Investigative Site

    Krakow, POL, 31-505, Poland

  • Novartis Investigative Site

    Katowice, Silesian Voivodeship, 40-650, Poland

  • Novartis Investigative Site

    Bydgoszcz, 85-065, Poland

  • Novartis Investigative Site

    Katowice, 40-689, Poland

  • Novartis Investigative Site

    Krakow, 31-870, Poland

  • Novartis Investigative Site

    Lublin, 20-410, Poland

  • Novartis Investigative Site

    Poznan, 61-731, Poland

  • Novartis Investigative Site

    Rzeszów, 35-055, Poland

  • Novartis Investigative Site

    Warsaw, 01-684, Poland

  • Novartis Investigative Site

    Lisbon, 1349-019, Portugal

  • Novartis Investigative Site

    Lisbon, 1649-035, Portugal

  • Novartis Investigative Site

    Porto, 4099-001, Portugal

  • Novartis Investigative Site

    Vila Nova de Gaia, 4434-502, Portugal

  • Novartis Investigative Site

    Belgrade, 11000, Serbia

  • Novartis Investigative Site

    Niš, 18108, Serbia

  • Novartis Investigative Site

    Daegu, 41404, South Korea

  • Novartis Investigative Site

    Gwangju, 61469, South Korea

  • Novartis Investigative Site

    Seoul, 03722, South Korea

  • Novartis Investigative Site

    Seoul, 04763, South Korea

  • Novartis Investigative Site

    Santiago Compostela, A Coruna, 15706, Spain

  • Novartis Investigative Site

    L'Hospitalet de Llobregat, Barcelona, 08907, Spain

  • Novartis Investigative Site

    Alicante, 03010, Spain

  • Novartis Investigative Site

    Barcelona, 08036, Spain

  • Novartis Investigative Site

    Lleida, 25198, Spain

  • Novartis Investigative Site

    Madrid, 28006, Spain

  • Novartis Investigative Site

    Málaga, 29010, Spain

  • Novartis Investigative Site

    Valencia, 46026, Spain

  • Novartis Investigative Site

    Inverness, Invernesshire, IV2 3RE, United Kingdom

  • Novartis Investigative Site

    Swinton, Manchester, M27 8FF, United Kingdom

  • Novartis Investigative Site

    Birmingham, West Midlands, B15 2TH, United Kingdom

  • Novartis Investigative Site

    London, NW1 2BU, United Kingdom

  • Novartis Investigative Site

    London, SW17 0QT, United Kingdom

  • Novartis Investigative Site

    Southampton, SO16 6YD, United Kingdom

  • Penn Presbyterian Medical Center

    Philadelphia, Pennsylvania, 19104, United States

  • Prairie Heart Institute

    Springfield, Illinois, 62769, United States

  • University of Chicago Medical Centr

    Chicago, Illinois, 60637, United States

  • Vanderbilt University Medical CenterX

    Nashville, Tennessee, 37221, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.